Express Scripts Holding Company (NASDAQ: ESRX) outpaced the market by gaining 11% last month compared to a 3% jump in the S&P 500, according to data provided by S&P Global Market Intelligence.
Continue Reading Below
The increase kept the stock ahead of the broader market so far in 2018, although shares have trailed indexes by a wide margin since early 2016.
The pharmacy-benefit manager announced second-quarter earnings early in the month that included slightly lower sales and higher profits. Adjusted claims fell 3.5% to match management's forecast while adjusted earnings rose thanks to cost cuts and prescription product upsells. "We are having a strong selling season across both commercial and health plans," CEO Tim Wentworth said in a press release.
Wentworth and his team lifted several of their operating forecasts for the fiscal year ahead thanks to rising retention rates and improved demand. Meanwhile, executives still expect to be acquired by Cigna in a deal that's likely to close before the end of 2018. That process took a big step forward when shareholders voted to approve the proposed merger on Aug. 24.
10 stocks we like better than Express ScriptsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Express Scripts wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018